The Nasal Drug Delivery Technology Market is driven by the rising demand for non-invasive administration methods that enhance patient compliance and bioavailability. Innovations such as advanced ...

ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions: Hørsholm, Denmark Tuesday, November 12, 2024, 12:00 Hrs [IST] ...

Since Permatan doesn’t rely on the same controversial active ingredient as nasal sprays, it is considered to be safer in ...

ALK has a market cap of $36.8bn. Neffy became the first and only approved nasal spray medicine to treat severe allergic ...

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected ... “ALK is a specialized pharmaceutical company and a global leader in the allergy field, serving ...

Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA ... needle-free emergency treatment for patients experiencing acute and ...

On Thursday, the FDA proposed removing oral phenylephrine from the list of approved active ingredients for over-the-counter ...

The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...

Medically reviewed by Daniel More, MD You can stop allergies with a variety of natural remedies, including breathing in steam ...